The Immunotherapy Foundation icon, an "if" inside a circle A blue and green "stop" X A DNA symbol in a ring An injection in a ring A pill in a ring A green and blue broken chain link A location icon A dark location icon A telephone icon A dark phone icon An email/letter icon A dark mail icon Facebook icon Facebook icon Twitter icon Twitter icon Instagram icon Instagram icon A hamburger menu A closing X icon A simple caret A systemic icon Bullseye A clock Reduced side-effects Resistance

Making Progress, Every Day.

Keep up with the latest trials and treatments

News & Updates Patient Resources Go T Cells Go!

All Trials & Treatments

Oropharyngeal Cancer

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03192345
Phase: 1
Sponsors: Sanofi
Date: Last Updated 7/6/2018
Regions: US; South; Investigational Site Number 8400003, Dallas, TX, 75230; US; South; Investigational Site 8400006, Nashville, TN, 37203; US; Northeast and Mid-Atlantic; Investigational Site Number 8400001 and Investigational Site Number 8400101, Boston, MA, 02114 and 02115; US; Midwest, Investigational Site Number 8400004, Fairway, KS, 66205
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext 1 then #

To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors, et al.

Pembrolizumab in Combination With CRT for LA-SCCHN

Trial Identifier: NCT02586207
Phase: 1
Sponsors: Sanford Health, Merck Sharp & Dohme Corp.
Date: Last updated 10/6/2017
Regions: US; Midwest; Sanford-Bismarck Medical Center, Bismarck, ND, 58501 and Sanford-Roger Maris Cancer Center, Fargo, ND, 58122; US; Midwest; Sanford Health Cancer Center, Sioux Falls, SD, 57104; US; West Coast, UCSD Moores Cancer Center, La Jolla, CA 92093
Contact: Sanford-Bismarck Medical Center: Tammy Fischer, RN, 701-323-5365,; Sanford-Roger Maris Cancer Center: Mary Schuster, RN, 701-234-7514,; Sanford Health Cancer Center: Central Referral Line 877-878-4825,; UCSD Moores Cancer Center: Mandy Natsuhara, 858-534-7613,

This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the head and neck (SCCHN). Approximately 39 patients with Stage III-IVB SCCHN will be enrolled to evaluate both the safety and efficacy of this novel combination. Subjects will not be randomized and will all receive the study treatment.

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Trial Identifier: NCT03554889
Phase: 1
Sponsors: Shangzhou Cancer Hospital, Shanghai Bokang Bioengineering Co., LTD
Date: Last updated 6/13/2018
Regions: Asia; China; Hangzhou Cancer Hospital, Hangzhou, Zhejiang, 310002
Contact: Shixiu Wu,+8657186826086,

This is a phase I clinical study of expanded NK cells from autologous origin. The NK cell will be selected and expanded ex vivo and infused back into patients. Nimotuzumab will be used 24 hours before infusion. 21 advanced cancer patients are planned to receive two cycles of NK cells and Nimotuzumab treatment. Biomarkers and immunological markers are collected and analyzed as well.

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Trial Identifier: NCT03187314
Sponsors: Hangzhou Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.
Date: 6/2017 (last updated 6/2017)
Regions: Asia; China; Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China, 310002 Contact: Shixiu Wu, MD +8657186826086 Contact: Zhao Jing, MD +8657156008656

The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 in patients with esophageal cancer

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)

Trial Identifier: NCT03189719
Sponsors: Merck Sharp & Dohme Corp.
Date: 6/2017 (last updated 6/2017)
Regions: Varied; Contact: Toll Free Number 1-888-577-8839, Please refer to this study by its identifier: NCT03189719

The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma.

The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03182673
Phase: 1
Sponsors: Jiangsu HengRui Medicine Co., Ltd.
Date: Last updated 2/28/2018
Regions: Asia, China, The Cancer Center, Sun Yat-sen University Guangzhou, Guangdong, 510060
Contact: RuiHua Xu, MD, PhD, 86-20-8734-3008, or Yi Liu, PhD, 86-21-6045-3192 ext 822,

This aim of study to assess the safety and tolerability of SHR7390 combined with SHR-1210 and to define Dose limiting toxicity(DLT)and the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Trial Identifier: NCT03174275
Phase: 1
Sponsors: UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Celgene
Date: Last updated 6/12/2018
Regions: US; South; Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, NC 27599
Contact: Jared Weiss, MD, 919-843-7718,

Participants in this study have locally-advanced SCCHN. In this study the investigators are testing the combination of carboplatin, nano-albumin bound paclitaxel and durvalumab. The purpose of this study is to test a combination of chemotherapy to hopefully both increase the number of subjects that respond to therapy while also decreasing the number of side effects that subjects experience.

Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)

Trial Identifier: NCT03179436
Phase: 1
Sponsors: Merck Sharp & Dohme Corp.
Date: Last updated 6/21/2018
Regions: Multiple Sites: USA, Australia, Israel, Japan, Korea; call Merck Trial Finder for site details.
Contact: Toll Free Number: 1-888-577-8839,

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.

Special Combination of OBP-301 and Pembrolizumab

Trial Identifier: NCT03172819
Sponsors: Toshihiko Doi, National Cancer Center Hospital East; Oncolys BioPharma Inc, Merck Sharp & Dohme Corp.
Date: 5/2017 (last updated 6/2017)
Regions: Asia; Japan; National Cancer Center Hospital East; Kashiwa, Chiba. Contact: Takashi Kojima, Dr +81-4-7133-1111 ext 91266

This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Trial Identifier: NCT03172624
Phase: 2
Sponsors: Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Date: Last updated 5/22/2018
Regions: USA; Northeast and Mid-Atlantic; Multiple sites in NY and NJ; Memoral Sloan Kettering Basking Ridge, Basking Ridge, NJ 07920; Memorial Sloan Kettering Monmouth, Middletown, NJ 07748; Memorial Sloan Kettering Commack, Commack, NY 11725; Memorial Sloan Kettering Westchester, Harrison, NY 10604; Memorial Sloan Kettering Cancer Center, New York, NY 10065; Memorial Sloan Kettering Rockville Centre, Rockville Centre, NY 11570
Contact: Alan Ho, MD, PhD, 646-888-4235,

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Trial Identifier: NCT03172936
Sponsors: Novartis
Date: 5/2017 (last updated 5/2017)
Regions: 1-888-669-6682, Please refer to trial identifier NCT03172936.

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Trial Identifier: NCT02834013
Sponsors: National Cancer Institute (NCI)
Date: 7/2016 (last updated 4/2017)
Regions: Multi-regions; see 555 study sites here

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Trial Identifier: NCT02628067
Sponsors: Merck Sharp & Dohme Corp.
Date: 12/2015 (last updated 2/2017)
Regions: Multi-regions; see 42 study locations

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Oropharyngeal Cancer (HPV+)

Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer

Trial Identifier: NCT03162224
Sponsors: MedImmune LLC
Date: 5/2017 (last updated 5/2017)
Regions: US; Northeast and Mid-Atlantic; Research Site Recruiting The Bronx, New York, United States, 10461; Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479, use NCT03162224

This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV DNA vaccine in combination with durvalumab (also known as MEDI4736) which is a human monoclonal antibody directed against PD-L1, which blocks the interaction of PD-L1 with PD-1 and CD80.

E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers

Trial Identifier: NCT02858310
Sponsors: National Cancer Institute (NCI)
Date: 8/2016 (last updated 4/2017)
Regions: US; Northeast and Mid-Atlantic; National Institutes of Health Clinical Center (Bethesda, Maryland)

Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have a HPV protein called E7 inside of their cells. In this new therapy, researchers take a person s blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer. Researchers want to see if this can help people. Objective: To determine a safe dose of E7 TCR cells and whether these cells can help patients.

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

Trial Identifier: NCT02865135
Sponsors: Dana Farber Cancer Institute, SU2C
Date: 7/2016 (last updated 12/2016)
Regions: US; Northeast and Mid-Atlantic; Dana-Farber Cancer Institute, Boston, MA

This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A*02).

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)

Trial Identifier: NCT02488759
Sponsors: Bristol-Myers Squibb
Date: 6/2015 (last updated 4/2017)
Regions: Multi-region; Recruiting sites have contact information. Please contact the sites directly:; Contact: First line of the email MUST contain NCT# and Site #

The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the types of tumors identified.

HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers, HESTIA

Trial Identifier: NCT02379520
Sponsors: Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System
Date: 2/2015 (last updated 2/2017)
Regions: US; South; Houston Methodist Hospital, Houston, Texas

The purpose of this study is to find the biggest dose of HPVSTs (special immune system cells) that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV associated cancers. If the treatment with HPVST cells alone proves safe (Group A), additional group of patients (Group B) will receive Nivolumab in addition to HPVST cells in a lymphodepleted environment. Nivolumab is an antibody therapy that helps T cells control the tumor and it is FDA approved for the treatment of certain types of cancers, including Hodgkin's lymphoma. Lymphodepletion will decrease the level of circulating T cells prior to infusion of HPVST cells, thereby giving them room to expand. The purpose of this part of the study is to find out if TGF-beta resistant HPVST cells in combination with Nivolumab are safe, how long they last in the body and if they are more effective than HPVST cells alone in controlling the tumor.

Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies

Trial Identifier: NCT02241369
Sponsors: Inovio Pharmaceuticals, University of Pennsylvania
Date: 9/2014 (last updated 8/2016)
Regions: US; Northeast and Mid-Atlantic; University of Pennsylvania, Philadelphia, PA 19104 Contact: Alison Berry 215-662-2847 Principal Investigator: Charu Aggarwal, MD

This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated aerodigestive precancerous lesions and malignancies.


Patient Diagram